In short
This article discusses a clinical trial investigating the effectiveness of two treatments, 2LEBV® and 2LXFS®, in reducing fatigue and other symptoms associated with Epstein-Barr Virus (EBV) infection. The study aims to compare these treatments against a placebo in a randomized, double-blind setting, focusing on patients aged 12 and older who experience significant fatigue and other EBV-related symptoms.
At a glance
- Study Type
- Randomized, placebo-controlled, double-blind clinical trial
- Treatments
- 2LEBV® and 2LXFS®/2LEBV® compared to placebo
- Target Condition
- Epstein-Barr Virus (EBV) infection with significant fatigue
- Primary Outcome
- Fatigue severity reduction at 6 months (end of treatment)
- Secondary Outcomes
- Other fatigue dimensions, EBV-related symptoms, lymphocyte typing, antibody levels
- Participant Age
- 12 years and older
- Study Duration
- 12 months (6 months treatment, 6 months follow-up)
- Key Measurements
- MFI-20 questionnaire, symptom assessment, blood tests
What is RIBONUCLEIC ACID K10?
RIBONUCLEIC ACID K10 is an active substance being studied as part of a medication called 2LXFS. This medication is currently undergoing clinical trials to evaluate its effectiveness in treating fatigue associated with Epstein-Barr Virus (EBV) infection. Ribonucleic acid, also known as RNA, is a crucial molecule in biological processes, and this specific form (K10) is being investigated for its potential therapeutic effects.
Target Condition: Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) infection is the primary condition being targeted in this study. EBV is a common virus that can cause various symptoms, including significant fatigue. The infection can be identified through the presence of EBV antigens or antibodies in the blood.
Potential Benefits
The main goal of using RIBONUCLEIC ACID K10 as part of the 2LXFS medication is to reduce fatigue severity in patients with EBV infection. The study aims to evaluate if this treatment can help alleviate the following symptoms often associated with EBV infection:
- Long-lasting exhaustion, even after light exertion
- Subfebrile state (slightly elevated body temperature) or fever
- Loss of appetite and nausea
- Sore throat and swollen lymph nodes
- Muscle weakness and joint pain
- Memory and attention problems
- Sleep disorders
- Various other symptoms affecting different body systems
Clinical Trial Details
The clinical trial for 2LXFS (which contains RIBONUCLEIC ACID K10) is designed as a randomized, placebo-controlled, double-blind study. This means that participants are randomly assigned to receive either the actual medication or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study. This design helps ensure the most accurate and unbiased results.
The study will measure the effectiveness of the treatment using various methods, including:
- The MFI-20 questionnaire, which assesses different aspects of fatigue
- Monitoring of EBV-related symptoms
- Analysis of immune system markers (lymphocyte typing and immunoglobulins)
How the Medication is Administered
2LXFS, which contains RIBONUCLEIC ACID K10, is administered in the form of pillules for oromucosal use. This means the medication is designed to be absorbed through the mucous membrane of the mouth. The maximum daily dose is 380 mg, with a total treatment amount of up to 68.4 g over a 6-month period.
Other Active Substances in the Medication
In addition to RIBONUCLEIC ACID K10, the 2LXFS medication contains several other active substances, including:
- Interferon alfa and gamma
- Interleukin-1 and Interleukin-2
- Deoxyribonucleic acid (DNA)
- Specific nucleic acids targeting chronic fatigue syndrome associated with various pathogens
- Tumor necrosis factor-alpha
These substances are believed to work together to potentially modulate the immune response and address the symptoms associated with EBV infection.
Eligibility for the Trial
To participate in the clinical trial, patients must meet specific criteria, including:
- Being 12 years of age or older
- Experiencing significant fatigue for at least one month
- Having at least two other symptoms related to EBV infection
- Testing positive for EBV antibodies
There are also several exclusion criteria, such as recent use of certain medications or the presence of specific medical conditions.
Safety Considerations
As with any clinical trial, the safety of participants is a top priority. The study will monitor for any adverse events or side effects throughout the treatment period. It's important to note that individuals with severe immunodeficiency diseases, those undergoing chemotherapy or radiotherapy, or those with certain genetic conditions affecting galactose metabolism are not eligible for the trial due to potential risks.
In conclusion, RIBONUCLEIC ACID K10, as part of the 2LXFS medication, shows promise in potentially treating fatigue and other symptoms associated with Epstein-Barr Virus infection. However, as the clinical trial is ongoing, its effectiveness and safety profile are still being evaluated. Patients interested in this treatment should consult with their healthcare providers and consider participating in clinical trials if eligible.